Clinical Trial Update: A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating TNM001 for the prevention of lower respiratory tract infections caused by respiratory syncytial virus in infants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• TNM001

Snippet

Sponsor: Zhuhai Trinomab Pharmaceutical Co., Ltd. | Conditions: Respiratory Syncytial Virus Infections | Phase 2, Phase 3 | Status: COMPLETED